NCT02654483

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Jean Yuh Tang · Academic / Other
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

Detailed description

Itch is the most common complaint reported by patients with EB of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus (itch) in patients with EB. Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin. VPD-737 (serlopitant), a novel drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. Each patient will be un-blinded individually after completing 3 months of study period. All patients who complete the study will be offered a 2-month period on active drug. Patient who received active drug in the first period will be contacted and asked if they would like to continue on active drug for an additional 2 months. Patients who received placebo in the first period will be contacted and asked if they would like to repeat the study on open label for 2 months.

Conditions

• Epidermolysis Bullosa
• Pruritus

Interventions

Type	Name	Description
DRUG	VPD-737	VPD-737 inhibits the receptor neurokinin-1.
OTHER	Placebo	Matching tablets to VPD-737 tablets without active drug

Timeline

• Start date: 2016-08-31
• Primary completion: 2018-06-28
• Completion: 2018-07-27
• First posted: 2016-01-13
• Last updated: 2020-03-23
• Results posted: 2019-07-02

Locations

1 site across 1 country: United States